Sage Therapeutics, Inc.
SAGE · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $571 | $492 | $330 | $441 |
| - Cash | $67 | $45 | $81 | $100 |
| + Debt | $11 | $12 | $12 | $10 |
| Enterprise Value | $515 | $458 | $261 | $352 |
| Revenue | $32 | $14 | $13 | $12 |
| % Growth | 125.1% | 9.7% | 8% | – |
| Gross Profit | $32 | $13 | $11 | $7 |
| % Margin | 100.2% | 95.3% | 88.4% | 55.5% |
| EBITDA | -$54 | -$67 | -$80 | -$101 |
| % Margin | -170.9% | -479.7% | -625.9% | -850.4% |
| Net Income | -$50 | -$62 | -$96 | -$94 |
| % Margin | -156.8% | -442.4% | -747.3% | -788.1% |
| EPS Diluted | -0.79 | -1.01 | -1.57 | -1.53 |
| % Growth | 21.8% | 35.7% | -2.6% | – |
| Operating Cash Flow | -$59 | -$82 | -$67 | -$82 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$59 | -$82 | -$67 | -$82 |